ASCO 2018, Chicago, May 31, 2018 – ACM Global Laboratories, an affiliate of Rochester Regional Health and one of the independent central labs in the industry specializing in central laboratory testing, toxicology, and diagnostic lab services, announced a new therapeutic service offering to support the specific testing needs of oncology clinical trials. ACM’s Smarter Testing™ for Oncology brings together key elements to optimize oncology clinical trial outcomes. Beginning with an in-house staff of subspecialty pathologists and access to a growing network of remote pathologists, a continuous commitment to state-of-the-art image analytics and an extensive test menu of immunohistochemical and molecular testing, ACM’s wide range of general and subspecialty services in surgical pathology, cytopathology, and clinical pathology support the precision medicine revolution taking place in oncology research.
With demand for pathological services in clinical trials on the rise and anatomic pathologists in increasingly short supply, access to subspecialized pathologists has never been more critical. In response to this increased demand, ACM has developed Smarter Testing for Oncology to deliver a unique service offering for clients conducting cancer research. Smarter Testing for Oncology is an extension of the company’s Smarter Testing consultative approach, which advocates working with sponsors and CROs to identify their endpoints and collaborate to find the optimal laboratory testing for their study.
“We have been conducting testing for oncology trials for many years and recognized the power of bringing these individual components together in a complete package for our clients,” said Matthew Turner, MD, Director of Pathology at ACM Global Laboratories. “Oncology trials have some distinct characteristics from other types of trials due to their complexity and need for biomarker analysis and companion diagnostics. Our team is ideally suited to address these trial nuances through our continuous exposure to complicated cancer resections that we see at Rochester Regional Health.”
The Smarter Testing for Oncology includes four key elements:
For more information on ACM's Smarter Testing for Oncology services or to schedule a meeting at ASCO, visit http://bit.ly/ACM-oncology, stop by Booth #6143 at the conference or connect with us - Twitter, LinkedIn and Facebook.
About ACM Global Laboratories
ACM Global Laboratories, an affiliate of Rochester Regional Health, is one of the largest global independent central labs in the industry. ACM is CAP and SAMHSA certified. The company delivers high-quality laboratory testing and diagnostic lab services in support of both clinical trials research, toxicology and individual patient care. ACM provides a powerful combination of operational excellence, scientific expertise, and unsurpassed global service to customers in more than 65 countries. ACM performs more than 30 million laboratory tests each year-spanning all medical disciplines including pathology, microbiology, molecular diagnostics, toxicology, and more. For more information, visit www.acmgloballab.com or call +1 866 405 0400.
About Rochester Regional Health
Rochester Regional Health is an integrated health services organization serving the people of Western New York, the Finger Lakes and beyond. The system includes five hospitals; primary and specialty practices, rehabilitation centers, ambulatory campuses and immediate care facilities; innovative senior services, facilities and independent housing; a wide range of behavioral health services; and Rochester Regional Health Laboratories and ACM Global Laboratories, a global leader in patient and clinical trials. Rochester Regional Health is the region’s second largest employer. Learn more at RochesterRegional.org.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.